Investors were cautious towards the end of the trading week as the UK's vote to leave the EU looms.
News & Analysis: Infinity Pharmaceuticals
Disappointing results from a clinical trial cause traders to head for the exits.
Infinity Pharmaceuticals' stock continued its recent nosedive in July. Is it now a compelling buy?
Infinity Pharmaceuticals stock is today's top gainer after forging a collaborative licensing deal for its lead experimental drug, IPI-145.
Economic data pushes the S&P 500 marginally lower as InterMune, Zulily, and Infinity Pharmaceuticals all exploded higher.
Shares of Infinity Pharmaceuticals jump by double-digits after reporting its fourth-quarter earnings results. Find out why investors would be wise to overlook the headline number and focus on this figure instead.
Let’s take a closer look at 3 revolutionary new cancer treatments from Inovio, Roche, ImmunoGen, and Gilead Sciences.
A mixed bag of clinical studies, a highly-awaited FDA panel thumbs-up, and an unwelcome subpoena from the Department of Health and Human Services for one biotech company are this week's top stories.
Infinity shares get a temporary boost after presenting a copious amount of preclinical and clinical data at the American Society of Hematology's annual meeting.
Infinity shares soar after it provides a pipeline update. Should investors welcome Infinity with open arms, or is the share price getting ahead of itself again?